Intercept Pharmaceuticals Inc

NASDAQ:ICPT   3:59:09 PM EDT
15.41
-0.20 (-1.28%)
Products

Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Published: 12/09/2021 12:46 GMT
Intercept Pharmaceuticals Inc (ICPT) - Intercept Announces Withdrawal of Ema Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to Nash.
Intercept Pharmaceuticals Inc - Intercept is in Process of Generating Additional Efficacy and Safety Data From Regenerate.
Intercept Pharmaceuticals Inc - Established Application Timeline Could Not Be Extended Any Further to Allow for Submission of Additional Data.
Intercept Pharmaceuticals Inc - Chmp Was Not Able to Determine a Positive Benefit-risk.